254744-14-4

Upstream product

• 127-09-3 sodium acetate 
• 190197-86-5 4-bromo-3-(bromomethyl)benzonitrile 
• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 127-08-2 potassium acetate 
• 41963-20-6 4-bromo-3-methylbenzonirtile 

Downstream Products

• 1268336-36-2 5-cyano-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1352344-84-3 C₁₃H₁₄BrNO₂ 
• 1352344-85-4 C₁₉H₂₆BNO₄ 
• 1352344-90-1 C₂₉H₃₇FN₂O₅ 
• 144025-14-9 (+)-Desmethylcitalopram 
• 128196-01-0 escitalopram 
• 905710-66-9 4-bromo-3-(hydroxymethyl)benzonitrile 

Relevant academic research and scientific papers

BORON-CONTAINING SMALL MOLECULES

Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.

BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS

This invention provides novel compounds of the following formula useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents

A series of boron-containing benzoxaborole compounds was designed and synthesized for a structure-activity relationship investigation surrounding 7-(HOOCCH2CH2)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (1) with the goal of discovering

Enantioenriched synthesis of Escitalopram using lithiation-borylation methodology

The asymmetric synthesis of Escitalopram has been completed using a lithiation-borylation reaction as the key step. Suitably functionalized enantioenriched carbamate (er 98:2) and boronic ester coupling partners were prepared and following deprotonation with s-BuLi and borylation, the tertiary alcohol was obtained in 42% yield and 93:7 er. The lithiation-borylation reaction was found to tolerate nitrile, benzylic alcohol and N-Boc functionalities. The tertiary alcohol was converted to Escitalopram in three further steps.

Compounds for the Treatment of Periodontal Disease

Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro- 1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis

A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro- 1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.